Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:5742 |
| Name | pancreatic acinar cell adenocarcinoma |
| Definition | A pancreatic adenocarcinoma that has_material_basis_in cells with morphological resemblance to acinar cells and is associated with increased serum lipase. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma pancreatic acinar cell adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | Dabrafenib + Trametinib | pancreatic acinar cell adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01537107 | Phase I | Sirolimus + Vismodegib | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03412799 | Phase I | Gemcitabine + Nab-paclitaxel + SBP-101 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Completed | USA | AUS | 0 |
| NCT04858334 | Phase II | Olaparib | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Recruiting | USA | ISR | 1 |
| NCT05286827 | Phase II | Olaparib | Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT06813079 | Phase II | Abemaciclib Ceritinib Selinexor Doxorubicin Etoposide Brigatinib Ponatinib Neratinib Cobimetinib | Using Tumor Models to Determine Treatments | Not yet recruiting | CAN | 0 |